San Francisco, Calif. (April 21, 2009) - Fluxion Biosciences announced today an exclusive distribution agreement with EuroClone S.p.A., headquartered in Milan, Italy. EuroClone will handle sales and service of Fluxion’s BioFlux research tools for live cell image analysis in Italy, Spain and Portugal as well as countries in Eastern Europe and Northern Africa. The contract includes the Czech Republic, Slovenia, Croatia, Bosnia Herzegovina, Serbia, Montenegro, Albania, Bulgaria, Rumania, Greece, Turnkey, Cyprus, Malta, Libya, Morocco, Tunisia and Algeria.
EuroClone S.p.A., founded in 1985, manufactures and distributes products for cell biology, molecular biology, cytogenetics, genomics and proteomics and immunology. With its team of researchers, product managers and sales and marketing and customer care professionals, the company is committed to bringing innovations to its laboratory customers.
“The agreement with EuroClone completes our network of sales and service coverage in Europe and reaffirms our leadership in shear-dependent cellular assays,” explained Mark Atlas, director of sales for Fluxion. “The relationship will complement EuroClone’s product portfolio and give us access to their cell biology customers.”
“We are pleased to have entered into this strategic distribution agreement with Fluxion,” commented Franco Aiolfi, president and CEO of EuropClone S.p.A. “Their product portfoilio has good synergy with our existing product range for cell biology and supports our mission to continuously deliver innovations to our customers .”
The Fluxion BioFlux 200 system is ideal for live cell imaging in applications such as cell adhesion and microbial biofilm studies. BioFlux 200 incorporates Fluxion’s proprietary microfluidic design to deliver an automated, reproducible system for studying live cells and biofilms under controlled-shear conditions. The system simulates in vivo physiological conditions more closely and at higher throughput than other approaches.
About Fluxion Biosciences
Fluxion Biosciences provides cellular analysis tools for use in critical life science research and drug discovery applications. Fluxion’s proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Fluxion’s systems meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use operating system for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
